Dupixent and CTCL: the new MDL is here, but the paperwork still matters most
A plain-English July 2026 update on Dupixent CTCL MDL 3180, what the JPML order says, and which records families should save now.
A plain-English July 2026 update on Dupixent CTCL MDL 3180, what the JPML order says, and which records families should save now.
A plain-English July 2026 update on Boston Scientific spinal cord stimulator MDL 3181, including shocks, burns, lead migration, revision surgery, and explant issues.
A July 2026 update on Depo-Provera meningioma lawsuits, MDL 3140 case growth, scientific evidence, FDA label changes, and records potential claimants should preserve.
A plain-English July 2026 update on Depo-Provera MDL 3140, including the case count, Rule 702 hearing, bellwether timeline, and records potential claimants should preserve.
A plain-English July 2026 update on Depo-Provera meningioma claims, MDL No. 3140 scheduling, Rule 702 expert hearings, and what records potential claimants should gather.
A July 2026 update on Depo-Provera meningioma lawsuits, the MDL 3140 Daubert hearing, first bellwether timeline, and records potential claimants may need.
A July 2026 update on Depo-Provera MDL 3140, including the June settlement-development order, the July 27 Rule 702 hearing, case counts, and records potential claimants should gather.
A July 2026 update on Depo-Provera meningioma claims, MDL 3140 case counts, label changes, records to gather, and bellwether timing.
A July 2026 update on Depo-Provera meningioma claims, MDL 3140 case counts, the Rule 702 schedule, FDA label warnings, and what families should collect before a legal review.
A plain-English July 2026 update on the Depo-Provera meningioma MDL, the JPML case count, FDA label language, and records families should gather.